Glucose-lowering effects of intestinal bile acid sequestration through enhancement of splanchnic glucose utilization

Trends in Endocrinology and Metabolism

Volumn 25, Issue 5, 2014, Pages 235-244

  Prawitt, Janne ^a,b,c,d   Caron, Sandrine ^a,b,c,d   Staels, Bart ^a,b,c,d  

^a France   (France)

^b UNIV LILLE   (France)

^c INSERM   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Bile acid sequestrant; FXR; Glucose homeostasis; TGR5; Type 2 diabetes

Indexed keywords

BILE ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE;

HOMEOSTASIS; HUMAN; INTESTINE; LIVER; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

BILE ACIDS AND SALTS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HOMEOSTASIS; HUMANS; INTESTINES; LIVER; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 84899482356     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.03.007     Document Type: Review

References (96)

1. Out C., et al. Bile acid sequestrants: more than simple resins. Curr. Opin. Lipidol. 2012, 23:43-55.
2. Garg A., et al. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann. Intern. Med. 1994, 121:416-422.
3. Lefebvre P., et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 2009, 89:147-191.
4. Porez G., et al. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J. Lipid Res. 2012, 53:1723-1737.
5. Abdelkarim M., et al. The farnesoid X Receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-γ and interfering with the Wnt/β-catenin pathways. J. Biol. Chem. 2010, 285:36759-36767.
6. Thomas C., et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009, 10:167-177.
7. Duran-Sandoval D., et al. The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J. Biol. Chem. 2005, 280:29971-29979.
8. Caron S., et al. Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. Mol. Cell. Biol. 2013, 33:2202-2211.
9. Cariou B., et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 2006, 281:11039-11049.
10. Ma K., et al. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 2006, 116:1102-1109.
11. Zhang Y., et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1006-1011.
12. Prawitt J., et al. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 2011, 60:1861-1871.
13. Katsuma S., et al. Bile acids promote glucagon-like peptide-1 secretion through tgr5 in a murine enteroendocrine cell line stc-1. Biochem. Biophys. Res. Commun. 2005, 329:386-390.
14. Popescu I.R., et al. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. FEBS Lett. 2010, 584:2845-2851.
15. Renga B., et al. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim. Biophys. Acta 2010, 1802:363-372.
16. Düfer M., et al. Bile acids acutely stimulate insulin secretion of mouse β-cells via farnesoid X receptor activation and K(ATP) channel inhibition. Diabetes 2012, 61:1479-1489.
17. Seyer P., et al. Hepatic glucose sensing is required to preserve β cell glucose competence. J. Clin. Invest. 2013, 123:1662-1676.
18. Nguyen A., et al. Bile acids and signal transduction: role in glucose homeostasis. Cell. Signal. 2008, 20:2180-2197.
19. Modica S., et al. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl. Recept. Signal. 2010, 8:e005.
20. Sayin S.I., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013, 17:225-235.
21. Hu X., et al. Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism. J. Intern. Med. 2013, 275:27-38.
22. Duran-Sandoval D., et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 2004, 53:890-898.
23. Meyer-Gerspach A.C., et al. Effects of chenodeoxycholic acid on the secretion of gut peptides and fibroblast growth factors in healthy humans. J. Clin. Endocrinol. Metab. 2013, 98:3351-3358.
24. Crestani M., et al. Hormonal regulation of the cholesterol 7 alpha-hydroxylase gene (CYP7). J. Lipid Res. 1995, 36:2419-2432.
25. Haeusler R.A., et al. Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes 2013, 62:4184-4191.
26. Gineste R., et al. Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol. Endocrinol. 2008, 22:2433-2447.
27. Berrabah W., et al. The glucose sensing O-GlcNacylation pathway regulates the nuclear bile acid receptor FXR. Hepatology 2013, 10.1002/hep.26710.
28. Balasubramaniyan N., et al. SUMOylation of the farnesoid X receptor (FXR) regulates the expression of FXR target genes. J. Biol. Chem. 2013, 288:13850-13862.
29. Kemper J.K., et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab. 2009, 10:392-404.
30. Yamagata K., et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J. Biol. Chem. 2004, 279:23158-23165.
31. De Fabiani E., et al. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J. Biol. Chem. 2003, 278:39124-39132.
32. Stayrook K.R., et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 2005, 146:984-991.
33. de Aguiar Vallim T.Q., et al. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013, 17:657-669.
34. Harach T., et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci. Rep. 2012, 2:430.
35. Park W.H., et al. Insulin-dependent suppression of cholesterol 7α-hydroxylase is a possible link between glucose and cholesterol metabolisms. Exp. Mol. Med. 2011, 43:571-579.
36. Li T., et al. Glucose stimulates cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes. J. Lipid Res. 2010, 51:832-842.
37. Li T., et al. Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity. J. Biol. Chem. 2012, 287:1861-1873.
38. Herrema H., et al. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptoralpha-controlled metabolic pathways in mice. Hepatology 2010, 51:806-816.
39. Watanabe M., et al. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J. Biol. Chem. 2011, 286:26913-26920.
40. Brufau G., et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 2010, 52:1455-1464.
41. Patti M., et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 2009, 17:1671-1677.
42. Gerhard G.S., et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care 2013, 36:1859-1864.
43. Steinert R.E., et al. Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial. Obesity (Silver Spring) 2013, 21:E660-E668.
44. Kohli R., et al. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J. Clin. Endocrinol. Metab. 2013, 98:E708-E712.
45. Goldberg R.B., et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch. Intern. Med. 2008, 168:1531-1540.
46. Bays H.E., et al. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch. Intern. Med. 2008, 168:1975-1983.
47. Fonseca V.A., et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008, 31:1479-1484.
48. Watanabe M., et al. Bile acid binding resin improves metabolic control through the induction of energy expenditure. PLoS ONE 2012, 7:e38286.
49. Schwartz S.L., et al. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab. Syndr. Relat. Disord. 2010, 8:179-188.
50. Beysen C., et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 2012, 55:432-442.
51. Henry R.R., et al. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2012, 14:40-46.
52. -/- mice. J. Biol. Chem. 2009, 284:10315-10323.
53. Li F., et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat. Commun. 2013, 4:2384.
54. Nwose O.M., et al. Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes. Clin. Med. Insights Endocrinol. Diabetes 2013, 6:75-79.
55. Shang Q., et al. The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302:G815-G823.
56. Chen L., et al. Cholestyramine reverses hyperglycemia and enhances GLP-1 release in Zucker diabetic fatty rats. J. Pharmacol. Exp. Ther. 2010, 334:164-170.
57. Kobayashi M., et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007, 56:239-247.
58. Sugimoto-Kawabata K., et al. Colestilan decreases weight gain by enhanced NEFA incorporation in biliary lipids and fecal lipid excretion. J. Lipid Res. 2013, 54:1255-1264.
59. Handelsman Y., et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr. Pract. 2010, 16:617-628.
60. Vega G.L., et al. Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome. Am. J. Cardiol. 2011, 108:1129-1135.
61. Potthoff M.J., et al. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 304:G371-G380.
62. Shang Q., et al. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298:G419-G424.
63. Adrian T.E., et al. Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers. Diabetologia 2012, 55:2343-2347.
64. Suzuki T., et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J. Nippon Med. Sch. 2007, 74:338-343.
65. Smushkin G., et al. The effect of a bile acid sequestrant on glucose metabolism in subjects with type 2 diabetes. Diabetes 2013, 62:1094-1101.
66. Marina A.L., et al. Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function. Diabetes Care 2012, 35:1119-1125.
67. Meissner M., et al. Bile acid sequestration reduces plasma glucose levels in db/db mice by increasing its metabolic clearance rate. PLoS ONE 2011, 6:e24564.
68. Zhang S., et al. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 2009, 51:380-388.
69. Cipriani S., et al. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. 2010, 51:771-784.
70. Ma Y., et al. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm. Res. 2013, 30:1447-1457.
71. McMahan R.H., et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J. Biol. Chem. 2013, 288:11761-11770.
72. Mudaliar S., et al. Efficacy and safety of the farnesoid x receptor agonist obeticholic Acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013, 145:574-582.
73. Haeusler R.A., et al. Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia. Cell Metab. 2012, 15:65-74.
74. Nakahara M., et al. Ileal bile acid-binding protein, functionally associated with the farnesoid X receptor or the ileal bile acid transporter, regulates bile acid activity in the small intestine. J. Biol. Chem. 2005, 280:42283-42289.
75. Alemi F., et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 2013, 144:145-154.
76. Le T., et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012, 56:922-932.
77. Goldberg R.B., et al. Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia. Diab. Vasc. Dis. Res. 2013, 10:256-262.
78. Cheung G.W.C., et al. Intestinal cholecystokinin controls glucose production through a neuronal network. Cell Metab. 2009, 10:99-109.
79. Lien F., et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J. Clin. Invest. 2014, 124:1037-1051.
80. Thomas C., et al. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 2008, 7:678-693.
81. Watanabe M., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006, 439:484-489.
82. Schoenfield L.J., et al. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety. Ann. Intern. Med. 1981, 95:257-282.
83. Bateson M.C., et al. Chenodeoxycholic acid therapy for hypertriglyceridaemia in men. Br. J. Clin. Pharmacol. 1978, 5:249-254.
84. Miller N.E., et al. Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. Lancet 1974, 2:929-931.
85. Leiss O., et al. Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstones. Scand. J. Gastroenterol. 1982, 17:587-592.
86. Bell G.D., et al. Gallstone dissolution in man using chenodeoxycholic acid. Lancet 1972, 2:1213-1216.
87. Parks D.J., et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284:1365-1368.
88. Makishima M., et al. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
89. Wang H., et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 1999, 3:543-553.
90. Grober J., et al. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoic acid receptor heterodimer. J. Biol. Chem. 1999, 274:29749-29754.
91. Ananthanarayanan M., et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J. Biol. Chem. 2001, 276:28857-28865.
92. Holt J.A., et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003, 17:1581-1591.
93. Kawamata Y., et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 2003, 278:9435-9440.
94. Wang Y., et al. Effects of chenodeoxycholic acid and deoxycholic acid on cholesterol absorption and metabolism in humans. Transl. Res. 2006, 148:37-45.
95. Inagaki T., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005, 2:217-225.
96. Pols T.W.H., et al. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J. Hepatol. 2011, 54:1263-1272.